The Drug Discovery World Podcast

Could a New Weight Loss Approach Have Longer Term Benefits than GLP-1s?

In this episode, Bruno Quinney talks with Vincent Marion, scientific founder of Adipo Pharma, about the company’s novel insulin‑sensitizing peptide, PATAS, which targets a specific protein‑protein interaction in adipocytes to restore glucose uptake and protect muscle mass. Marion explains how adipose tissue dysfunction drives whole‑body insulin resistance and why this pathway has been overlooked in drug development compared to liver and muscle targets. He contrasts PATAS with GLP‑1 agonists, noting that while GLP‑1s are effective for weight loss, they can cause significant muscle loss and may lack long‑term metabolic durability. Pre‑clinical data show PATAS improves insulin sensitivity, reduces fatty liver, and preserves muscle, and early Phase 1 results in healthy volunteers are promising.